ArticleOpen forum infectious diseases2026

Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial.

Jutta E Laiho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.